BofA's Top Biotech Picks for 2026: ARGX & VRTX

BofA's Top Biotech Selections

Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its leading large-cap biotech selections for 2026. The firm has set ambitious price targets of $1,013 for Argenx and $598 for Vertex, signaling significant confidence in their future growth prospects.

Key Catalysts and Growth Drivers

For Argenx, BofA highlighted the strong commercial performance of its drug Vvygart and key upcoming phase 3 trial results. Vertex's selection is underpinned by its dominant cystic fibrosis franchise, which generates substantial cash flow to support its expanding pipeline into new therapeutic areas like rare kidney diseases.

Broader Sector Recommendations

The analysis also extended to small and mid-cap stocks, with KalVista Pharmaceuticals (NASDAQ:KALV) and Rhythm Pharmaceuticals (NASDAQ:RYTM) named as top commercial-stage picks. These selections indicate a bullish outlook across various segments of the biotech industry based on specific therapeutic advancements.

Summary and Investor Outlook

Bank of America's report underscores a clear focus on companies with proven commercial execution and significant clinical catalysts on the horizon. These strategic picks offer a roadmap for investors monitoring key growth drivers in the biotechnology sector leading up to 2026.

FAQ

Q: Which companies are BofA's top large-cap biotech picks?
A: Bank of America named Argenx (ARGX) and Vertex Pharmaceuticals (VRTX) as its top selections.

Q: What are the price targets for Argenx and Vertex?
A: The price target for Argenx is $1,013, and the target for Vertex is $598.

Source: Investing.com